The Future of Ketamine and Mood Disorders In 2019, the FDA and European Fee approved using an esketamine nasal spready beneath the brand name title Spravato to treat melancholy. However, as of 2021, ketamine has not been authorized because of the FDA to treat despair or other psychological wellness disorders, https://alant630cef8.wikinewspaper.com/user